PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28906150-4 2017 METHODS: The present study was designed to prospectively monitor changes in cardiac parameters, both structural and functional, in patients with ATTR cardiomyopathy while treated with a TTR specific antisense oligonucleotide (ASO; IONIS-TTRRx) designed to lower blood levels of the amyloid fibril precursor protein. Oligonucleotides, Antisense 226-229 transthyretin Homo sapiens 146-149 35322226-4 2022 Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies have been shown to be highly effective for the blockade of TTR expression in the liver in humans. Oligonucleotides, Antisense 60-63 transthyretin Homo sapiens 137-140 33155274-8 2021 By sequence-specific mRNA knockdown, the approved small interfering RNA (siRNA) patisiran and antisense oligonucleotide (ASO) inotersen both significantly reduce plasma TTR levels and improve neuropathy and quality of life compared to placebo. Oligonucleotides, Antisense 121-124 transthyretin Homo sapiens 169-172 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides, Antisense 99-102 transthyretin Homo sapiens 117-120 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides, Antisense 99-102 transthyretin Homo sapiens 149-152 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 6-9 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 135-138 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 93-96 27584576-2 2016 Two compounds that knockdown TTR, comprising a small interfering RNA (siRNA; ALN-TTR-02) and an antisense oligonucleotide (ASO; IONIS-TTRRx), are currently being evaluated in clinical trials. Oligonucleotides, Antisense 123-126 transthyretin Homo sapiens 29-32 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 105-108 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 115-118 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 115-118 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. Oligonucleotides, Antisense 140-143 transthyretin Homo sapiens 52-55 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. Oligonucleotides, Antisense 140-143 transthyretin Homo sapiens 127-130 20462362-7 2010 Suppression of choroid TTR expression by intraventricular administered ASO may offer a medical means of treating leptomeningeal amyloidosis. Oligonucleotides, Antisense 71-74 transthyretin Homo sapiens 23-26 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 16421881-5 2006 As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. Oligonucleotides, Antisense 103-107 transthyretin Homo sapiens 142-145